<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">PENICILLAMINE</span><br/>(pen-i-sill'a-meen)<br/><span class="topboxtradename">Cuprimine, </span><span class="topboxtradename">Depen<br/></span><b>Classifications:</b> <span class="classification">chelating agent</span><br/><b>Pregnancy Category: </b>D<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>150 mg, 250 mg capsules; 250 mg tablets</p>
<h1><a name="action">Actions</a></h1>
<p>Thiol compound prepared by hydrolysis of penicillin but lacking antibacterial activity. Also combines chemically with cystine
         to form a soluble disulfide complex that prevents stone formation and may even dissolve existing cystic stones. Mechanism
         of action in rheumatoid arthritis not known but appears to be related to inhibition of collagen formation. Cross-sensitivity
         between penicillin and penicillamine can occur.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Forms stable soluble chelate with copper, zinc, iron, lead, mercury, and possibly other heavy metals and promotes their excretion
         in urine. With Wilson's disease, therapeutic effectiveness is indicated by improvement in psychiatric and neurologic symptoms,
         visual symptoms, and liver function. In some patients, neurologic symptoms become more prominent during initial therapy and
         then subside. With rheumatoid arthritis, improvement in grip strength, decrease in stiffness following immobility, reduction
         of pain, decrease in sedimentation rate and rheumatoid factor.
      </p>
<h1><a name="uses">Uses</a></h1>
<p>To promote renal excretion of excess copper in Wilson's disease (hepatolenticular degeneration). Active rheumatoid arthritis
         in patients who have failed to respond to conventional therapy. Cystinuria.
      </p>
<h1><a name="unlabeleduses">Unlabeled Uses</a></h1>
<p>Scleroderma, primary biliary cirrhosis, porphyria cutanea tarda, lead poisoning.</p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Hypersensitivity to penicillamine or to any penicillin; history of penicillamine-related aplastic anemia or agranulocytosis;
         patients with rheumatoid arthritis who have renal insufficiency or who are pregnant; pregnancy (category D), lactation; concomitant
         administration with drugs that can cause severe hematologic or renal reactions (e.g., antimalarials, gold salts, immunosuppressants,
         oxyphenbutazone, phenylbutazone).
      </p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Allergy-prone individuals.</p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Wilson's Disease</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 250 mg q.i.d., with 3 doses 1 h a.c. and the last dose at least 2 h after the last meal<br/><span class="rdage">Child:</span> <span class="rdroute">PO</span> 20 mg/kg/d in 24 divided doses (max: 1 g/d)<br/><br/><span class="indicationtitle">Cystinuria</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 250500 mg q.i.d., with doses adjusted to limit urinary excretion of cystine to 100200 mg/d<br/><span class="rdage">Child:</span> <span class="rdroute">PO</span> 30 mg/kg/d in 4 divided doses with doses adjusted to limit urinary excretion of cystine to 100200 mg/d<br/><br/><span class="indicationtitle">Rheumatoid Arthritis</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 125250 mg/d; may increase at 13 mo intervals up to 11.5 g/d<br/><span class="rdage">Child:</span> <span class="rdroute">PO</span> 3 mg/kg/d (<img src="../images/special/lesserorequal.gif"/>250 mg/d) times 3 mo, then 6 mg/kg/d (<img src="../images/special/lesserorequal.gif"/>500
               mg/d) in 2 divided doses times 3 mo [max: of 10 mg/kg/d (<img src="../images/special/lesserorequal.gif"/>1.5 g/d) in 34
               divided doses]<br/><br/><span class="indicationtitle">Lead Poisoning</span><br/><span class="rdage">Child:</span> <span class="rdroute">PO</span> 3040 mg/kg/d in 34 divided doses (max: 1.5 g/d); initiate at 25% target dose, grad ually increase to full dose over 23 wk<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Oral</span><br/><ul>
<li>Give on empty stomach (60 min before or 2 h after meals) to avoid absorption of metals in foods by penicillamine.</li>
<li>Give contents in 1530 mL of chilled fruit juice or pureed fruit (e.g., applesauce) if patient cannot swallow capsules
            or tablets.
         </li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">Body as a Whole:</span> Fever, arthralgia, lymphadenopathy, thyroiditis, SLE-like syndrome, thrombophlebitis, hyperpyrexia, myasthenia gravis syndrome,
      tingling of feet, weakness. <span class="typehead">GI:</span>
<span class="speceff-common">Anorexia, nausea, vomiting,</span> epigastric pain, diarrhea, oral lesions, <span class="speceff-common">reduction or loss of taste perception (particularly salt and sweet), metallic taste,</span> activation of peptic ulcer, pancreatitis. <span class="typehead">Urogenital:</span> Membranous glomerulopathy, <span class="speceff-common">proteinuria,</span> hematuria. <span class="typehead">Hematologic:</span> Thrombocytopenia, leukopenia, <span class="speceff-life">agranulocytosis</span>, thrombotic thrombocytopenic purpura, <span class="speceff-life">hemolytic anemia, aplastic anemia</span>. <span class="typehead">Metabolic:</span> Pyridoxine deficiency. <span class="typehead">Skin:</span>
<span class="speceff-common">Generalized pruritus, urticaria,</span> mammary hyperplasia, alveolitis, skin friability, excessive skin wrinkling,<span class="speceff-common"> early and late occurring rashes,</span> pemphigus-like rash, alopecia. <span class="typehead">Special Senses:</span> Tinnitus, optic neuritis, ptosis. 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span>
<span class="classification">antimalarials</span>, <span class="classification">cytotoxics</span>, <b>gold</b> therapy may potentiate hematologic and renal adverse effects; <b>iron</b> may decrease penicillamine absorption. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> Readily absorbed from GI tract. <span class="typehead">Peak:</span> 1 h. <span class="typehead">Distribution:</span> Crosses placenta. <span class="typehead">Metabolism:</span> Metabolized in liver. <span class="typehead">Elimination:</span> Excreted in urine and feces. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Lab tests: Check WBC with differential, direct platelet counts, Hgb, and urinalyses prior to initiation of therapy and every
            3 d during the first month of therapy, then every 2 wk thereafter. Perform liver function tests and eye examinations before
            start of therapy and at least twice yearly thereafter.
         </li>
<li>Withhold drug and contact physician if the patient with rheumatoid arthritis develops proteinuria &gt;1 g (some clinicians accept
            &gt;2 g) or if platelet count drops to 3, or platelet count falls below 35004000/mm<sup>3</sup>, or neutropenia occurs.
         </li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>
            							Note: Clinical evidence of therapeutic effectiveness may not be apparent until 13 mo of drug therapy.
            						
         </li>
<li>Take exactly as prescribed. Allergic reactions occur in about one third of patients receiving penicillamine. Temporary interruptions
            of therapy increase possibility of sensitivity reactions.
         </li>
<li>Take temperature nightly during first few months of therapy. Fever is a possible early sign of allergy.</li>
<li>Observe skin over pressure sites: knees, elbows, shoulder blades, toes, buttocks. Penicillamine increases skin friability.</li>
<li>Report unusual bruising or bleeding, sore mouth or throat, fever, skin rash, or any other unusual symptoms to physician.</li>
<li>Do not breast feed while taking this drug.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>